These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8706852)

  • 21. Two distinct phosphorylation pathways have additive effects on Abl family kinase activation.
    Tanis KQ; Veach D; Duewel HS; Bornmann WG; Koleske AJ
    Mol Cell Biol; 2003 Jun; 23(11):3884-96. PubMed ID: 12748290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell cycle arrest by tyrosine kinase Abl involves altered early mitogenic response.
    Mattioni T; Jackson PK; Bchini-Hooft van Huijsduijnen O; Picard D
    Oncogene; 1995 Apr; 10(7):1325-33. PubMed ID: 7731683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of Abl Tyrosine Kinases with SOCS3 Impairs Its Suppressor Function in Tumorigenesis.
    Feng R; Wang X; Li J; Chen K; Guo G; Liao Y; Sun L; Huang S; Chen JL
    Neoplasia; 2018 Nov; 20(11):1095-1105. PubMed ID: 30236924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA.
    Kipreos ET; Wang JY
    Science; 1992 Apr; 256(5055):382-5. PubMed ID: 1566087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.
    Okuda K; D'Andrea A; Etten RA; Griffin JD
    J Clin Invest; 1997 Oct; 100(7):1708-15. PubMed ID: 9312168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphorylation of Bruton's tyrosine kinase by c-Abl.
    Bäckesjö CM; Vargas L; Superti-Furga G; Smith CI
    Biochem Biophys Res Commun; 2002 Dec; 299(3):510-5. PubMed ID: 12445832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The carboxyl terminus of v-Abl protein can augment SH2 domain function.
    Warren D; Heilpern AJ; Berg K; Rosenberg N
    J Virol; 2000 May; 74(10):4495-504. PubMed ID: 10775585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase.
    Oda T; Kujovich J; Reis M; Newman B; Druker BJ
    Oncogene; 1997 Sep; 15(11):1255-62. PubMed ID: 9315092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
    Liu J; Wu Y; Arlinghaus RB
    Cancer Res; 1996 Nov; 56(22):5120-4. PubMed ID: 8912843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib mesylate (STI571)-induced cell edge translocation of kinase-active and kinase-defective Abelson kinase: requirements of myristoylation and src homology 3 domain.
    Fujita A; Shishido T; Yuan Y; Inamoto E; Narumiya S; Watanabe N
    Mol Pharmacol; 2009 Jan; 75(1):75-84. PubMed ID: 18835981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites.
    Ren R; Ye ZS; Baltimore D
    Genes Dev; 1994 Apr; 8(7):783-95. PubMed ID: 7926767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II.
    Zvara A; Fajardo JE; Escalante M; Cotton G; Muir T; Kirsch KH; Birge RB
    Oncogene; 2001 Feb; 20(8):951-61. PubMed ID: 11314030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.
    Hawk N; Sun T; Xie S; Wang Y; Wu Y; Liu J; Arlinghaus RB
    Cancer Res; 2002 Jan; 62(2):386-90. PubMed ID: 11809685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
    Gishizky ML; Cortez D; Pendergast AM
    Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional interaction between the c-Abl and Arg protein-tyrosine kinases in the oxidative stress response.
    Cao C; Leng Y; Li C; Kufe D
    J Biol Chem; 2003 Apr; 278(15):12961-7. PubMed ID: 12569093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling.
    Li S; Couvillon AD; Brasher BB; Van Etten RA
    EMBO J; 2001 Dec; 20(23):6793-804. PubMed ID: 11726515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogenic activation of c-ABL by mutation within its last exon.
    Goga A; McLaughlin J; Pendergast AM; Parmar K; Muller A; Rosenberg N; Witte ON
    Mol Cell Biol; 1993 Aug; 13(8):4967-75. PubMed ID: 8336729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases.
    Cao C; Leng Y; Huang W; Liu X; Kufe D
    J Biol Chem; 2003 Oct; 278(41):39609-14. PubMed ID: 12893824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of c-Fes tyrosine kinase activity by coiled-coil and SH2 domains: analysis with Saccharomyces cerevisiae.
    Takashima Y; Delfino FJ; Engen JR; Superti-Furga G; Smithgall TE
    Biochemistry; 2003 Apr; 42(12):3567-74. PubMed ID: 12653561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility.
    Lamontanara AJ; Georgeon S; Tria G; Svergun DI; Hantschel O
    Nat Commun; 2014 Nov; 5():5470. PubMed ID: 25399951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.